Backers included SV Life Sciences Advisers, Health Enterprise Partners, Ascension Ventures and Square 1 Bank.
The company intends to use the funds for the continued development as well as sales and marketing of CAM™ in the U.S. and Europe.
Led by Gust Bardy, M.D., founder, and Jon Hunt, PhD, President and CEO, Bardy Diagnostics is commercializing the Carnation Ambulatory Monitor (“CAM™”), a small and light P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device worn by patients to record heart rhythms for extended periods of time.
The data file can be downloaded for analysis at a hospital or clinic or at a third-party reading site, whichever the customer prefers.
It is approved for use in the U.S. and Europe and fits within existing reimbursement codes in each region.
FinSMEs
05/01/2017